Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults

NCT02062281 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

2225

Enrollment

NETWORK

Sponsor class

Conditions

Pneumococcal Infection
Influenza

Interventions

BIOLOGICAL: 23-valent pneumococcal polysaccharide vaccine
BIOLOGICAL: trivalent influenza vaccine
BIOLOGICAL: 23vPPV+TIV

Sponsor

Jiangsu Province Centers for Disease Control and Prevention

Collaborators

[object Object]
[object Object]